Volume 15, Issue 10 pp. 1135-1139

A novel presenilin 2 mutation (V393M) in early-onset dementia with profound language impairment

S. G. Lindquist

S. G. Lindquist

Memory Disorders Research Group, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark

Section of Neurogenetics, Institute of Cellular and Molecular Medicine, The Panum Institute, University of Copenhagen, Copenhagen, Denmark

Search for more papers by this author
L. Hasholt

L. Hasholt

Section of Neurogenetics, Institute of Cellular and Molecular Medicine, The Panum Institute, University of Copenhagen, Copenhagen, Denmark

Search for more papers by this author
J. M. C. Bahl

J. M. C. Bahl

Department of Autoimmunology, Statens Serum Institut, Copenhagen, Denmark

Search for more papers by this author
N. H. H. Heegaard

N. H. H. Heegaard

Department of Autoimmunology, Statens Serum Institut, Copenhagen, Denmark

Search for more papers by this author
B. B. Andersen

B. B. Andersen

Memory Disorders Research Group, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark

Search for more papers by this author
A. Nørremølle

A. Nørremølle

Section of Neurogenetics, Institute of Cellular and Molecular Medicine, The Panum Institute, University of Copenhagen, Copenhagen, Denmark

Search for more papers by this author
J. Stokholm

J. Stokholm

Memory Disorders Research Group, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark

Search for more papers by this author
M. Schwartz

M. Schwartz

Department of Clinical Genetics, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark

Search for more papers by this author
M. Batbayli

M. Batbayli

Department of Clinical Genetics, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark

Search for more papers by this author
H. Laursen

H. Laursen

Department of Pathology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark

Search for more papers by this author
R. Pardossi-Piquard

R. Pardossi-Piquard

Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada

Search for more papers by this author
F. Chen

F. Chen

Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada

Search for more papers by this author
P. St George-Hyslop

P. St George-Hyslop

Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada

Search for more papers by this author
G. Waldemar

G. Waldemar

Memory Disorders Research Group, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark

Search for more papers by this author
J. E. Nielsen

J. E. Nielsen

Memory Disorders Research Group, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark

Section of Neurogenetics, Institute of Cellular and Molecular Medicine, The Panum Institute, University of Copenhagen, Copenhagen, Denmark

Search for more papers by this author
First published: 05 September 2008
Citations: 18
Suzanne G. Lindquist, MD, Memory Disorders Research Group 6702, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark (tel.: +45 35456247; fax: +45 35456272; e-mail: [email protected]).

Abstract

Background: Mutations in the Presenilin 2 gene (PSEN2) are rare causes of Alzheimer’s disease (AD). Pathogenic mutations in the genes associated with autosomal dominant inherited AD have been shown to alter processing of the amyloid precursor protein (APP) resulting in a relative increase of the amount of Aβ42 peptide.

Methods and results: We present a patient with neuropathologically confirmed early-onset AD characterized by profound language impairment. The patient was heterozygous for a novel missense mutation in exon 11 of the PSEN2 gene leading to a predicted amino acid substitution from valine to methionine in position 393, a conserved residue. However, in vitro expression of PSEN2 V393M cDNA did not result in detectable increase of the secreted Aβ42/40 peptide ratio. The mutation was not found in 384 control individuals tested.

Conclusions: The possible pathogenic nature of the mutation is not clarified. We discuss the limitations of functional PSEN2 studies and the challenges associated with genetic counselling of family members at risk.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.